- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03304470
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
March 19, 2018 updated by: UNION therapeutics
A Double-Blind, Randomized, Intraindividual, Vehicle-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Topically Applied ATx201 in Subjects With Moderate Atopic Dermatitis
This is a Phase 2, 3-week, single-center, double-blind, randomized, two-arm, vehicle controlled study, with each individual receiving both active and vehicle treatment.
Approximately 30 subjects with moderate atopic dermatitis will receive topically applied ATx201 CREAM 2% and matching vehicle once daily for 3 weeks (5 mg/cm2/day), without occlusion.
ATx201 and vehicle will be applied on two separate target lesions of moderate atopic dermatitis (lesions of at least 3 × 3 cm, excluding the face, scalp, genitals, hands, and feet, ideally from the same anatomical location).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H2K 4L5
- Innovaderm Research Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- clinically confirmed diagnosis of active atopic dermatitis
- at least a 6-month history of atopic dermatitis and had no significant flares in atopic dermatitis for at least 4 weeks before screening
- ≥2 areas of atopic dermatitis (excluding face, scalp, genitals, hands, and feet) of at least 3 × 3 cm; with a lesional TSS of ≥5 at Day 1 for each treatment area
Exclusion Criteria:
- breastfeeding, pregnant, or is planning to become pregnant during the study.
- clinically infected atopic dermatitis
- Fitzpatrick's Skin Phototype ≥5
- Presence of any tattoos, scratches, open sores, excessive hair, or skin damages in the target lesion areas
- known to have immune deficiency or is immunocompromised.
- history of cancer or lymphoproliferative disease within 5 years prior to Day 1.
- major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.
- clinically significant medical condition or physical/laboratory/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.
- known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or infection with human immunodeficiency virus).
- used hydroxyzine or diphenhydramine within 1 week prior to Day 1.
- used dupilumab within 12 weeks prior to Day 1.
- received any nonbiological investigational product or device within 4 weeks prior to Day 1
- used crisaborole and any other topical PDE-4 inhibitor within 4 weeks prior to Day 1.
- used doxepin within 1 week prior to Day 1.
- used topical products containing urea within 1 week prior to Day 1.
- used nonurea-containing emollient anywhere on the body from 1 day before Day 1.
- used systemic antibiotics or topical antibiotics on the treated areas within 2 weeks prior to Day 1.
- used any topical medicated treatment for atopic dermatitis within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, calcineurin inhibitors, tars, bleach, antimicrobials, medical devices, and bleach baths.
- used systemic treatments (other than biologics) that could affect atopic dermatitis less than 4 weeks prior to Day 1 (e.g., retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide [hydroxyurea], azathioprine, oral/injectable corticosteroids).
- received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
- excessive sun exposure, is planning a trip to a sunny climate, has received ultraviolet phototherapy, or has used tanning booths within 4 weeks prior to Day 1, or is not willing to minimize natural and artificial sunlight exposure during the study. Use of sunscreen products (excluding the treatment areas) and protective apparel are recommended when exposure cannot be avoided.
- known or suspected allergy to ATx201 or any component of the investigational product.
- known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.
- history of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics.
- history of hypertrophic scarring or keloid formation in scars or suture sites.
- taking anticoagulant medication, such as heparin, low molecular weight-heparin, warfarin, or antiplatelets (nonsteroidal anti-inflammatory drugs and aspirin ≤81 mg will not be considered antiplatelets) within 2 weeks prior to Day 1, or has a contraindication to skin biopsies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ATx201 2% CREAM
|
Anhydrous Cream
|
Placebo Comparator: ATx201 Cream Vehicle
|
Anhydrous Cream
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of local and systemic treatment-emergent adverse events
Time Frame: 34 days
|
# of TEAEs
|
34 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in lesional Total Sign Score at Days 8, 15, and 22.
Time Frame: 22 Days
|
22 Days
|
Change from baseline in lesional Treatment Areas Assessment at Days 8, 15, and 22
Time Frame: 22 Days
|
22 Days
|
Change from baseline in skin barrier and biomarker levels at Day 22
Time Frame: Day 22
|
Day 22
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Philippe Prokocimer, Sponsor CMO
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 25, 2017
Primary Completion (Actual)
March 5, 2018
Study Completion (Actual)
March 5, 2018
Study Registration Dates
First Submitted
September 25, 2017
First Submitted That Met QC Criteria
October 3, 2017
First Posted (Actual)
October 9, 2017
Study Record Updates
Last Update Posted (Actual)
March 20, 2018
Last Update Submitted That Met QC Criteria
March 19, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATx201-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on ATx201 2% Cream
-
UNION therapeuticsCompletedIrritation Potential of Topic AgentUnited States
-
UNION therapeuticsCompleted
-
UNION therapeuticsCompletedAtopic DermatitisBulgaria, Denmark, Poland
-
UNION therapeuticsCompleted
-
UNION therapeuticsCompleted
-
LEO PharmaCompletedImpetigo | Secondarily Infected Traumatic Lesions (SITL)United States
-
Betta Pharmaceuticals Co., Ltd.Quintiles, Inc.Completed
-
University of ParmaCompletedInflammatory Response | Endotoxemia | Oxidative Stress | Glucose, High BloodItaly
-
Taro Pharmaceuticals USACompleted
-
Jamaica Hospital Medical CenterJohnson & JohnsonUnknownTinea Pedis | Athlete's Foot | Foot Fungus | RingwormUnited States